06.18.2025
Disease Management
$1,505,272.00
36 months
SAPPHIRE: Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients with a History of Cancer.
Expand the SAPPHIRE Registry to gain a better understanding of how medications for inflammatory bowel disease impact the risk of new and recurring cancers in patients with a history of cancer. Researchers also plan to include patients with IBD who currently have active cancer to gain insights into whether cancer influences IBD disease activity or the usage of IBD medications.